Skip to main content
Spyre Therapeutics, Inc. logo

Spyre Therapeutics, Inc. — Investor Relations & Filings

Ticker · SYRE ISIN · US00773J1034 LEI · 52990017AIJPRH3HQH40 US Manufacturing
Open in API
Filings indexed 740 across all filing types
Latest filing 2022-08-26 Director's Dealing
Country US United States of America
Listing US SYRE

About Spyre Therapeutics, Inc.

https://spyre.com/

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation therapeutics for patients with inflammatory bowel disease (IBD) and other immune-mediated conditions. The company's approach involves engineering novel antibodies with prolonged activity in the body, which allows for less frequent dosing. Its pipeline targets validated biological mechanisms and explores the use of these antibodies as both monotherapies and in rational combination therapies. Spyre aims to provide treatment options for various gastrointestinal and rheumatic diseases that offer the potential for enhanced efficacy and greater convenience.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2022-08-26 English
FORM 4 SUBMISSION
Director's Dealing
2022-08-26 English
FORM 4 SUBMISSION
Director's Dealing
2022-08-26 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the departure of the CEO, appointment of an interim CEO, appointment of a Chief Business Officer, and a company restructuring with headcount reduction. These are announcements related to changes in senior management and organizational structure. There are no financial statements or detailed financial performance data present, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a proxy statement or voting results announcement. The document fits the category of Board/Management Information (MANG) because it announces changes in the company's board of directors and senior management positions. The document length is sufficient and contains detailed information about management changes, supporting a high confidence classification as MANG.
2022-08-25 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text includes an announcement about the submission and validation of a Marketing Authorization Application (MAA) to the European Medicines Agency. It contains forward-looking statements and references to regulatory filings but does not include financial statements or detailed financial analysis. The document is not an annual or quarterly report, audit report, earnings release, or any other detailed financial report. It is a regulatory announcement of a material event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2022-08-18 English
10-Q
Interim / Quarterly Report Q2 2022
2022-08-04 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.